Market Overview

UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises PT on Celgene Corporation

Share:
Related CELG
Goldman Sachs Previews ASCO Cancer Conference With Amgen, Celgene And Clovis Oncology
Morgan Stanley Looks Over Celgene's Quarter

In a report published Monday, BMO Capital Markets reiterated its Outperform rating on Celgene Corporation (NASDAQ: CELG), and raised its price target from $101.00 to $113.00.

BMO Capital Markets noted, “We reiterate our Outperform rating on shares of CELG and increase our price target to $113. Review of longer-term estimates suggests that the high end of 2017 EPS guidance of $13-$14 is realistic and that an EPS CAGR of 23%+ should support further multiple expansion. We continue to believe that Abraxane pancreatic cancer data on January 24 will be better than expected, MM-020 frontline data for Revlimid will support front-line filing in Europe, and multiple levers remain available to exceed near-, intermediate- and long-term guidance.”

Celgene Corporation closed on Friday at $96.30.

Latest Ratings for CELG

DateFirmActionFromTo
Feb 2015JefferiesMaintainsBuy
Jan 2015Deutsche BankMaintainsBuy
Jan 2015CitigroupMaintainsBuy

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings

 

Related Articles (CELG)

Around the Web, We're Loving...